S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.49 (+1.26%)
MSFT   141.56 (+1.44%)
AMZN   1,768.17 (+1.83%)
NVDA   196.42 (+5.30%)
MU   46.46 (+3.54%)
BABA   175.32 (+2.43%)
F   9.08 (+2.83%)
ACB   3.76 (+7.13%)
PRI   123.70 (+1.84%)
BAC   29.76 (+2.09%)
S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.49 (+1.26%)
MSFT   141.56 (+1.44%)
AMZN   1,768.17 (+1.83%)
NVDA   196.42 (+5.30%)
MU   46.46 (+3.54%)
BABA   175.32 (+2.43%)
F   9.08 (+2.83%)
ACB   3.76 (+7.13%)
PRI   123.70 (+1.84%)
BAC   29.76 (+2.09%)
Log in

Allergy Therapeutics Stock Price, News & Analysis (LON:AGY)

GBX 12.15
0.00 (0.00 %)
(As of 10/15/2019 04:00 PM ET)
Today's Range
12.08
Now: GBX 12.15
12.08
50-Day Range
11.15
MA: GBX 12.17
13.20
52-Week Range
8
Now: GBX 12.15
22.50
Volume2,439 shs
Average Volume167,682 shs
Market Capitalization£77.29 million
P/E Ratio24.30
Dividend YieldN/A
BetaN/A
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1903-844700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£73.72 million
Cash FlowGBX 4.32 per share
Book ValueGBX 5.90 per share

Profitability

Miscellaneous

Employees500
Market Cap£77.29 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.


Allergy Therapeutics (LON:AGY) Frequently Asked Questions

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

What price target have analysts set for AGY?

1 equities research analysts have issued 1-year price objectives for Allergy Therapeutics' shares. Their forecasts range from GBX 35 to GBX 40. On average, they expect Allergy Therapeutics' stock price to reach GBX 37.50 in the next year. This suggests a possible upside of 208.6% from the stock's current price. View Analyst Price Targets for Allergy Therapeutics.

What is the consensus analysts' recommendation for Allergy Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergy Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergy Therapeutics.

Has Allergy Therapeutics been receiving favorable news coverage?

Headlines about AGY stock have been trending neutral on Tuesday, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Allergy Therapeutics earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Allergy Therapeutics.

Who are some of Allergy Therapeutics' key competitors?

What other stocks do shareholders of Allergy Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergy Therapeutics investors own include Relypsa (RLYP), Repros Therapeutics (RPRX), Spectrum Pharmaceuticals (SPPI), Verastem (VSTM), Berkeley Energia (BKY), Burford Capital (BUR), Dechra Pharmaceuticals (DPH), Flowtech Fluidpower (FLO), Shanta Gold (SHG) and Sosandar (SOS).

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the folowing people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 55)
  • Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 54)
  • Ms. Beverly Lees, Group Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 12.15.

How big of a company is Allergy Therapeutics?

Allergy Therapeutics has a market capitalization of £77.29 million and generates £73.72 million in revenue each year. Allergy Therapeutics employs 500 workers across the globe.View Additional Information About Allergy Therapeutics.

What is Allergy Therapeutics' official website?

The official website for Allergy Therapeutics is http://www.allergytherapeutics.com/.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.


MarketBeat Community Rating for Allergy Therapeutics (LON AGY)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  335 (Thanks for Voting!)
Underperform Votes:  182 (Thanks for Voting!)
Total Votes:  517
MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote "Outperform" if you believe AGY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel